World Journal of Urology

, Volume 30, Issue 2, pp 131–135

Predicting prostate cancer many years before diagnosis: how and why?

Topic paper

Abstract

Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis and overtreatment. One way to shift the ratio of benefits to harm is to focus on men at highest risk, who have more to benefit than average. Neither family history nor any of the currently identified genomic markers offer sufficient risk stratification for practical use. However, there is considerable evidence that the levels of PSA in blood are strongly prognostic of the long-term risk of aggressive prostate cancer. Specifically, it is difficult to justify continuing to screen men aged 60 or older if they have a PSA less than 1 or 2 ng/ml; for men 45–60, intervals between PSA tests can be based on PSA levels, with 2–4-year retesting interval for men with PSA of 1 ng/ml or higher, and tests every 6–8 years for men with PSA <1 ng/ml. Men with the top 10% of PSAs at a young age (PSA ~1.5 ng/ml or higher below 50) are at particularly high risk and should be subject to intensive monitoring.

Keywords

Prostatic neoplasms Early detection of cancer Prostate-specific antigen 

References

  1. 1.
    Thompson IM, Lucia MS, Tangen CM (2007) Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: “what has been will be again, what has been done will be done again; there is nothing new under the sun.” ECCLESIASTES 1:9. Int J Epidemiol 36(2):287–289. doi:10.1093/ije/dym056 PubMedCrossRefGoogle Scholar
  2. 2.
    Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96(18):1358–1367. doi:10.1093/jnci/djh259 PubMedCrossRefGoogle Scholar
  3. 3.
    Xu J, Sun J, Kader AK, Lindstrom S, Wiklund F, Hsu FC, Johansson JE, Zheng SL, Thomas G, Hayes RB, Kraft P, Hunter DJ, Chanock SJ, Isaacs WB, Gronberg H (2009) Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 69(14):1565–1572. doi:10.1002/pros.21002 PubMedCrossRefGoogle Scholar
  4. 4.
    Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16):2215–2220PubMedCrossRefGoogle Scholar
  5. 5.
    Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N (1995) Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 87(5):354–360PubMedCrossRefGoogle Scholar
  6. 6.
    Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J (1994) Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344(8937):1594–1598PubMedCrossRefGoogle Scholar
  7. 7.
    Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273(4):289–294PubMedCrossRefGoogle Scholar
  8. 8.
    Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H (2006) Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 52(2):235–239. doi:10.1373/clinchem.2005.050641 PubMedCrossRefGoogle Scholar
  9. 9.
    Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D, Vickers AJ (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117(6):1210–1219. doi:10.1002/cncr.25568 PubMedCrossRefGoogle Scholar
  10. 10.
    Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H (2010) Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (Clin Res Ed) 341:c4521. doi:10.1136/bmj.c4521 CrossRefGoogle Scholar
  11. 11.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. doi:10.1056/NEJMoa0810084 PubMedCrossRefGoogle Scholar
  12. 12.
    Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725–732. doi:10.1016/s1470-2045(10)70146-7 PubMedCrossRefGoogle Scholar
  13. 13.
    Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65(2):343–346. doi:10.1016/j.urology.2004.09.046 PubMedCrossRefGoogle Scholar
  14. 14.
    Bul M, van Leeuwen PJ, Zhu X, Schroder FH, Roobol MJ (2011) Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol 59(4):498–505. doi:10.1016/j.eururo.2011.01.001 PubMedCrossRefGoogle Scholar
  15. 15.
    van Leeuwen PJ, Connolly D, Tammela TL, Auvinen A, Kranse R, Roobol MJ, Schroder FH, Gavin A (2010) Balancing the harms and benefits of early detection of prostate cancer. Cancer 116(20):4857–4865. doi:10.1002/cncr.25474 PubMedCrossRefGoogle Scholar
  16. 16.
    Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2008) Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study. Int J Cancer 123(5):1154–1159. doi:10.1002/ijc.23591 PubMedCrossRefGoogle Scholar
  17. 17.
    Brandt A, Bermejo JL, Sundquist J, Hemminki K (2010) Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 58(2):275–280. doi:10.1016/j.eururo.2010.02.002 PubMedCrossRefGoogle Scholar
  18. 18.
    Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358(9):910–919. doi:10.1056/NEJMoa075819 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations